Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for <i>BRAF</i>-mutant advanced melanoma: Phase 1 KEYNOTE-022 study.
Antoni Ribas(University of California, Los Angeles), Omid Hamid(Cedars-Sinai Medical Center), Donald P. Lawrence(Massachusetts General Hospital), Georgina V. Long(The University of Sydney), Scott J. Diede(Merck & Co., Inc., Rahway, NJ, USA (United States)), Matteo S. Carlino(The University of Sydney), F. Stephen Hodi(Harvard University), Yingjie Huang, Alexander Starodub(Dana-Farber Cancer Institute), Victoria Atkinson(Greenslopes Private Hospital), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rosalie Fisher(Auckland City Hospital), Wilson H. Miller(Jewish General Hospital)
Cited by 49
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k